Mathew J. Garnett
Wellcome Trust Sanger Institute
164 Papers
384 Citations
Mathew J. Garnett is an academic researcher from Wellcome Trust Sanger Institute. The author has contributed to research in topics: Cancer & Biology. The author has an hindex of 42, co-authored 142 publications. Previous affiliations of Mathew J. Garnett include Institute of Cancer Research & University of British Columbia.
Chat about Author
Papers
Base editing screens map mutations affecting interferon-γ signaling in cancer
Matthew A. Coelho,Sarah Cooper,Magdalena E. Strauß,Emre Karakoc,Shriram G. Bhosle,Emanuel Gonçalves,Gabriele Picco,Thomas Burgold,Chiara M Cattaneo,Vivien Veninga,Sarah Consonni,Cansu Dincer,Sara Vieira,Freddy Gibson,Syd Barthorpe,Claire Hardy,Joel Rein,Mark G. Thomas,John C. Marioni,Emile E. Voest,Andrew R. Bassett,Mathew J. Garnett +21 more
TL;DR: In this article , the authors systematically investigate the genetic determinants of IFN-γ response in colorectal cancer cells using CRISPR-Cas9 screens and base editing mutagenesis.
51
Patient-specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies
TL;DR: An approach that couples ex vivo high-throughput screenings of cancer biopsies using microfluidics with logic-based modeling to generate patient-specific dynamic models of extrinsic and intrinsic apoptosis signaling pathways is presented.
49
JACKS: joint analysis of CRISPR/Cas9 knock-out screens
TL;DR: Jacks, a Bayesian method that jointly analyses screens performed with the same guide RNA library, modeling the variable guide efficacies greatly improves hit identification, and allows a 2.5-fold reduction in required cell numbers without sacrificing performance compared to current analysis standards.
48
Stratification and prediction of drug synergy based on target functional similarity
Mi Yang,Patricia Jaaks,Jonathan R. Dry,Mathew J. Garnett,Michael P. Menden,Julio Saez-Rodriguez +5 more
- 02 Jun 2020
TL;DR: An approach to prioritization of drug combinations in high-throughput screens and to stratify synergistic responses to maximize the efficacy of drugs already known to induce synergy, ultimately enabling patient stratification.
Drug mechanism-of-action discovery through the integration of pharmacological and CRISPR screens
Emanuel Gonçalves,Aldo Segura-Cabrera,Clare Pacini,Gabriele Picco,Fiona M. Behan,Patricia Jaaks,Elizabeth A. Coker,Donny van der Meer,Andrew Barthorpe,Howard Lightfoot,Gdsc Screening Team,Andrew R. Leach,James T. Lynch,Ben Sidders,Claire Crafter,Francesco Iorio,Stephen Fawell,Mathew J. Garnett +17 more
TL;DR: Linking drug and gene dependency together with genomic datasets uncovered contexts in which molecular networks when perturbed mediate cancer cell loss-of-fitness, and thereby provide independent and orthogonal evidence of biomarkers for drug development.
44